Blood and CSF biomarkers in brain subcortical ischemic vascular disease: Involved pathways and clinical applicability

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 1, 2016, Pages 55-71

  Vilar Bergua, A ^a   Riba Llena, I ^a   Nafria C ^a   Bustamante, A ^a   Llombart, V ^a   Delgado, P ^a   Montaner, J ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

brain ischemia; cerebrospinal fluid; cerebrovascular diseases; vascular cognitive impairment; white matter disease

Indexed keywords

ACROLEIN; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; MICRORNA; NEOPTERIN; SCLEROPROTEIN; BIOLOGICAL MARKER; CYTOKINE;

BLOOD; BLOOD CLOTTING DISORDER; BRAIN ISCHEMIA; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INFLAMMATION; LIPID METABOLISM; NEUROIMAGING; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SUBCORTICAL ISCHEMIC VASCULAR DISEASE; WHITE MATTER LESION; BLOOD CLOTTING; COMPLICATION; LACUNAR STROKE; MULTIINFARCT DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION; WHITE MATTER;

BIOMARKERS; BLOOD COAGULATION; BRAIN ISCHEMIA; CYTOKINES; DEMENTIA, VASCULAR; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX PROTEINS; HUMANS; LIPID METABOLISM; MAGNETIC RESONANCE IMAGING; RENIN-ANGIOTENSIN SYSTEM; STROKE, LACUNAR; WHITE MATTER;

EID: 84951567210     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.68     Document Type: Review

References (135)

1. Jokinen H, Kalska H, MäntyläR, Pohjasvaara T, Ylikoski R, Hietanen M, et al. Cognitive profile of subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 2006; 77: 28-33
2. Rosenberg GA, Bjerke M and Wallin A. Multimodal markers of inflammation in the subcortical ischemic vascular disease type of vascular cognitive impairment. Stroke 2014; 45: 1531-1538
3. Wardlaw JM, Smith C and Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 2013; 12: 483-497
4. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9: 689-701
5. Economos A, Wright CB, Moon YP, Rundek T, Rabbani L, Paik MC, et al. Interleukin 6 plasma concentration associates with cognitive decline: the northern Manhattan study. Neuroepidemiology 2013; 40: 253-259
6. Riba-Llena I, Penalba A, Pelegri D, Vilar A, Jarca CI, Filomena J, et al. Role of lipoprotein-associated phospholipase A activity for the prediction of silent brain infarcts in women. Atherosclerosis 2014; 237: 811-815
7. Vermeer SE, Longstreth WT Jr. and Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol 2007; 6: 611-619
8. Fanning JP, Wong AA and Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Med 2014; 12: 119
9. Zhu YC, Dufouil C, Tzourio C and Chabriat H. Silent brain infarcts: a review of MRI diagnostic criteria. Stroke 2011; 42: 1140-1145
10. Raz N, Yang Y, Dahle CL and Land S. Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. Biochim Biophys Acta 2012; 1822: 361-369
11. Kertesz A, Black SE, Tokar G, Benke T, Carr T and Nicholson L. Periventricular and subcortical hyperintensities on magnetic resonance imaging. 'Rims, caps, and unidentified bright objects'. Arch Neurol 1988; 45: 404-408
12. Fazekas F, Niederkorn K, Schmidt R, Offenbacher H, Horner S, Bertha G, et al. White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. Stroke 1988; 19: 1285-1288
13. Brun A and Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986; 19: 253-262
14. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, et al. Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord 2009; 28: 348-356
15. Conklin J, Silver FL, Mikulis DJ and Mandell DM. Are acute infarcts the cause of leukoaraiosis? Brain mapping for 16 consecutive weeks. Ann Neurol 2014; 76: 899-904
16. van Swieten JC, van den Hout JH, van Ketel BA, Hijdra A, Wokke JH and van Gijn J. Periventricular lesions in the white matter on magnetic resonance imaging in the elderly. A morphometric correlation with arteriolosclerosis and dilated perivascular spaces. Brain 1991; 114: 761-774
17. Zhu YC, Tzourio C, Soumare A, Mazoyer B, Dufouil C and Chabriat H. Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: a population-based study. Stroke 2010; 41: 2483-2490
18. Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage 2004; 23: 708-716
19. Apostolova LG and Thompson PM. Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment. Neuropsychologia 2008; 46: 1597-1612
20. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
21. Sullivan GW, Sarembock IJ and Linden J. The role of inflammation in vascular diseases. J Leukoc Biol 2000; 67: 591-602
22. Amor S, Peferoen LA, Vogel DY, Breur M, van der Valk P, Baker D, et al. Inflammation in neurodegenerative diseases- An update. Immunology 2014; 142: 151-166
23. Pradhan AD, Manson JE, Rifai N, Buring JE and Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334
24. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM and Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951
25. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818
26. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-2322
27. Miwa K, Tanaka M, Okazaki S, Furukado S, Sakaguchi M, Mochizuki H, et al. Association between interleukin-6 levels and first-ever cerebrovascular events in patients with vascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33: 400-405
28. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H and Hori M. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke 2005; 36: 768-772
29. Yoshida M, Tomitori H, Machi Y, Katagiri D, Ueda S, Horiguchi K, et al. Acrolein, IL-6 and CRP as markers of silent brain infarction. Atherosclerosis 2009; 203: 557-562
30. Yoshida M, Higashi K, Kobayashi E, Saeki N, Wakui K, Kusaka T, et al. Correlation between images of silent brain infarction, carotid atherosclerosis and white matter hyperintensity, and plasma levels of acrolein, IL-6 and CRP. Atherosclerosis 2010; 211: 475-479
31. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C and Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology 2012; 78: 720-727
32. Ishikawa J, Tamura Y, Hoshide S, Eguchi K, Ishikawa S, Shimada K, et al. Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. Stroke 2007; 38: 911-917
33. Anan F, Shimomura T, Kaku T, Kaneda K, Imagawa M, Tsukagawa H, et al. High-sensitivity C-reactive protein level is a significant risk factor for silent cerebral infarction in patients on hemodialysis. Metabolism 2008; 57: 66-70
34. Kikuchi H, Anan F, Kaneda K, Nawata T, Eshima N, Saikawa T, et al. Interleukin-6 and silent cerebral infarction in hemodialysis patients: a cross-sectional study. Eur J Neurol 2011; 18: 625-630
35. Fornage M, Chiang YA, O'Meara ES, Psaty BM, Reiner AP, Siscovick DS, et al. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: the Cardiovascular Health Study. Stroke 2008; 39: 1952-1959
36. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005; 112: 900-905
37. Schmidt R, Schmidt H, Pichler M, Enzinger C, Petrovic K, Niederkorn K, et al. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study. Stroke 2006; 37: 2910-2916
38. Wright CB, Moon Y, Paik MC, Brown TR, Rabbani L, Yoshita M, et al. Inflammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke 2009; 40: 3466-3471
39. Nagai K, Kozaki K, Sonohara K, Akishita M and Toba K. Relationship between interleukin-6 and cerebral deep white matter and periventricular hyperintensity in elderly women. Geriatr Gerontol Int 2011; 11: 328-332
40. Rouhl RP, Damoiseaux JG, Lodder J, Theunissen RO, Knottnerus IL, Staals J, et al. Vascular inflammation in cerebral small vessel disease. Neurobiol Aging 2012; 33: 1800-1806
41. Aribisala BS, Wiseman S, Morris Z, Valdes-Hernandez MC, Royle NA, Maniega SM, et al. Circulating inflammatory markers are associated with magnetic resonance imaging-visible perivascular spaces but not directly with white matter hyperintensities. Stroke 2014; 45: 605-607
42. Marsland AL, Gianaros PJ, Abramowitch SM, Manuck SB and Hariri AR. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry 2008; 64: 484-490
43. Baune BT, Ponath G, Rothermundt M, Roesler A and Berger K. Association between cytokines and cerebral MRI changes in the aging brain. J Geriatr Psychiatry Neurol 2009; 22: 23-34
44. Jefferson AL, Massaro JM, Wolf PA, Seshadri S, Au R, Vasan RS, et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 2007; 68: 1032-1038
45. Wada M, Nagasawa H, Kurita K, Koyama S, Arawaka S, Kawanami T, et al. Cerebral small vessel disease and C-reactive protein: results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci 2008; 264: 43-49
46. de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001; 70: 9-14
47. van den Heuvel DM, Admiraal-Behloul F, ten Dam VH, Olofsen H, Bollen EL, Murray HM, et al. Different progression rates for deep white matter hyperintensities in elderly men and women. Neurology 2004; 63: 1699-1701
48. Deanfield JE, Halcox JP and Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-1295
49. Sarchielli P, Nardi K, Chiasserini D, Eusebi P, Tantucci M, Di Piero V, et al. Immunological profile of silent brain infarction and lacunar stroke. PLoS One 2013; 8: e68428
50. Kawamura T, Umemura T, Kanai A, Nagashima M, Nakamura N, Uno T, et al. Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type 2 diabetes mellitus. Metabolism 2006; 55: 461-466
51. Umemura T, Kawamura T, Sakakibara T, Kanai A, Sano T, Hotta N, et al. Association of soluble adhesion molecule and C-reactive protein levels with silent brain infarction in patients with and without type 2 diabetes. Curr Neurovasc Res 2008; 5: 106-111
52. Fassbender K, Bertsch T, Mielke O, Muhlhauser F and Hennerici M. Adhesion molecules in cerebrovascular diseases. Evidence for an inflammatory endothelial activation in cerebral large-and small-vessel disease. Stroke 1999; 30: 1647-1650
53. Hassan A, Hunt BJ, O'Sullivan M, Parmar K, Bamford JM, Briley D, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003; 126: 424-432
54. Han JH, Wong KS, Wang YY, Fu JH, Ding D and Hong Z. Plasma level of sICAM-1 is associated with the extent of white matter lesion among asymptomatic elderly subjects. Clin Neurol Neurosurg 2009; 111: 847-851
55. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H and Schmidt R. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005; 36: 1410-1414
56. de Leeuw FE, de Kleine M, Frijns CJ, Fijnheer R, van Gijn J and Kappelle LJ. Endothelial cell activation is associated with cerebral white matter lesions in patients with cerebrovascular disease. Ann NY Acad Sci 2002; 977: 306-314
57. Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, Jacques PF, et al. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 2008; 65: 642-649
58. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004; 127: 212-219
59. Kloppenborg RP, Geerlings MI, Visseren FL, Mali WP, Vermeulen M, van der Graaf Y, et al. Homocysteine and progression of generalized small-vessel disease: the SMART-MR Study. Neurology 2014; 82: 777-783
60. Khan U, Hassan A, Vallance P and Markus HS. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke 2007; 38: 411-413
61. Pavlovic AM, Pekmezovic T, Obrenovic R, Novakovic I, Tomic G, Mijajlovic M, et al. Increased total homocysteine level is associated with clinical status and severity of white matter changes in symptomatic patients with subcortical small vessel disease. Clin Neurol Neurosurg 2011; 113: 711-715
62. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010; 5: e12244
63. Hankey GJ, Ford AH, Yi Q, Eikelboom JW, Lees KR, Chen C, et al. Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis. Stroke 2013; 44: 2232-2239
64. Clarke R, Bennett D, Parish S, Lewington S, Skeaff M, Eussen SJ, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr 2014; 100: 657-666
65. Pikula A, Boger RH, Beiser AS, Maas R, DeCarli C, Schwedhelm E, et al. Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke 2009; 40: 2959-2964
66. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006; 66: 23-29
67. Gomis M, Sobrino T, Ois A, Millan M, Rodriguez-Campello A, Perez de la Ossa N, et al. Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype. Stroke 2009; 40: 3197-3201
68. van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM, Koudstaal PJ, et al. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 2004; 55: 570-575
69. Kaffashian S, Tzourio C, Soumare A, Dufouil C, Zhu Y, Crivello F, et al. Plasma beta-amyloid and MRI markers of cerebral small vessel disease: Three-City Dijon Study. Neurology 2014; 83: 2038-2045
70. Wada M, Nagasawa H, Kurita K, Koyama S, Arawaka S, Kawanami T, et al. Microalbuminuria is a risk factor for cerebral small vessel disease in community-based elderly subjects. J Neurol Sci 2007; 255: 27-34
71. Delgado P, Riba-Llena I, Tovar JL, Jarca CI, Mundet X, Lopez-Rueda A, et al. Prevalence and associated factors of silent brain infarcts in a Mediterranean cohort of hypertensives. Hypertension 2014; 64: 658-663
72. Knopman DS, Mosley TH Jr., Bailey KR, Jack CR Jr., Schwartz GL and Turner ST. Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships. J Neurol Sci 2008; 271: 53-60
73. Pikula A, Beiser AS, DeCarli C, Himali JJ, Debette S, Au R, et al. Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the Framingham Offspring Study. Circulation 2012; 125: 2100-2107
74. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4: 1186-1193
75. Kozuka K, Kohriyama T, Nomura E, Ikeda J, Kajikawa H and Nakamura S. Endothelial markers and adhesion molecules in acute ischemic stroke-sequential change and differences in stroke subtype. Atherosclerosis 2002; 161: 161-168
76. Tomimoto H, Akiguchi I, Ohtani R, Yagi H, Kanda M, Shibasaki H, et al. The coagulation-fibrinolysis system in patients with leukoaraiosis and Binswanger disease. Arch Neurol 2001; 58: 1620-1625
77. Gottesman RF, Cummiskey C, Chambless L, Wu KK, Aleksic N, Folsom AR, et al. Hemostatic factors and subclinical brain infarction in a community-based sample: the ARIC study. Cerebrovasc Dis 2009; 28: 589-594
78. Kario K, Matsuo T, Kobayashi H, Hoshide S and Shimada K. Hyperinsulinemia and hemostatic abnormalities are associated with silent lacunar cerebral infarcts in elderly hypertensive subjects. J Am Coll Cardiol 2001; 37: 871-877
79. Nagai M, Hoshide S and Kario K. Association of prothrombotic status with markers of cerebral small vessel disease in elderly hypertensive patients. Am J Hypertens 2012; 25: 1088-1094
80. Kearney-Schwartz A, Rossignol P, Bracard S, Felblinger J, Fay R, Boivin JM, et al. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke 2009; 40: 1229-1236
81. Hassan A, Lansbury A, Catto AJ, Guthrie A, Spencer J, Craven C, et al. Angiotensin converting enzyme insertion/ deletion genotype is associated with leukoaraiosis in lacunar syndromes. J Neurol Neurosurg Psychiatry 2002; 72: 343-346
82. Brenner D, Labreuche J, Pico F, Scheltens P, Poirier O, Cambien F, et al. The renin-angiotensin-aldosterone system in cerebral small vessel disease. J Neurol 2008; 255: 993-1000
83. Jochemsen HM, Geerlings MI, Grool AM, Vincken KL, Mali WP, van der Graaf Y, et al. Angiotensin-converting enzyme and progression of white matter lesions and brain atrophy-the SMART-MR study. J Alzheimers Dis 2012; 29: 39-49
84. Konnecke H and Bechmann I. The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas. Clin Dev Immunol 2013; 2013: 914104
85. Rosenberg GA, Sullivan N and Esiri MM. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 2001; 32: 1162-1168
86. Romero JR, Vasan RS, Beiser AS, Au R, Benjamin EJ, DeCarli C, et al. Association of matrix metalloproteinases with MRI indices of brain ischemia and aging. Neurobiol Aging 2010; 31: 2128-2135
87. Gouw AA, van der Flier WM, Fazekas F, van Straaten EC, Pantoni L, Poggesi A, et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 2008; 39: 1414-1420
88. Schilling S, Tzourio C, Dufouil C, Zhu Y, Berr C, Alperovitch A, et al. Plasma lipids and cerebral small vessel disease. Neurology 2014; 83: 1844-1852
89. Willey JZ, Gardener H, Moon YP, Yoshita M, DeCarli C, Cheung YK, et al. Lipid profile components and subclinical cerebrovascular disease in the northern Manhattan study. Cerebrovasc Dis 2014; 37: 423-430
90. Gregson J, Stirnadel-Farrant HA, Doobaree IU and Koro C. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature. Atherosclerosis 2012; 225: 11-21
91. Fitzpatrick AL, Irizarry MC, Cushman M, Jenny NS, Chi GC and Koro C. Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study. Atherosclerosis 2014; 235: 384-391
92. Dadu RT, Fornage M, Virani SS, Nambi V, Hoogeveen RC, Boerwinkle E, et al. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke 2013; 44: 1803-1808
93. Heo SH and Lee SH. High levels of serum uric acid are associated with silent brain infarction. J Neurol Sci 2010; 297: 6-10
94. Shih CY, Chen CY, Wen CJ, Liu HM and Kuo HK. Relationship between serum uric acid and cerebral white matter lesions in the elderly. Nutr Metab Cardiovasc Dis 2012; 22: 154-159
95. Hudson BI, Moon YP, Kalea AZ, Khatri M, Marquez C, Schmidt AM, et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis 2011; 216: 192-198
96. Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, et al. Cerebrospinal fluid biomarkers of white matter lesions-cross-sectional results from the LADIS study. Eur J Neurol 2010; 17: 377-382
97. Jonsson M, Zetterberg H, Rolstad S, Edman A, Gouw AA, Bjerke M, et al. Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study. Dement Geriatr Cogn Disord 2012; 34: 61-67
98. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A and Andreasson U. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J Alzheimers Dis 2011; 27: 665-676
99. Rosengren LE, Karlsson JE, Sjogren M, Blennow K and Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999; 52: 1090-1093
100. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001; 66: 510-516
101. Wallin A, Sjogren M, Edman A, Blennow K and Regland B. Symptoms, vascular risk factors and blood-brain barrier function in relation to CT whitematter changes in dementia. Eur Neurol 2000; 44: 229-235
102. Candelario-Jalil E, Thompson J, Taheri S, Grossetete M, Adair JC, Edmonds E, et al. Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment. Stroke 2011; 42: 1345-1350
103. Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, et al. Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. Dement Geriatr Cogn Dis Extra 2011; 1: 31-42
104. Paternoster L, Chen W and Sudlow CL. Genetic determinants of white matter hyperintensities on brain scans: a systematic assessment of 19 candidate gene polymorphisms in 46 studies in 19,000 subjects. Stroke 2009; 40: 2020-2026
105. Debette S, Bis JC, Fornage M, Schmidt H, Ikram MA, Sigurdsson S, et al. Genome-wide association studies of MRI-defined brain infarcts: meta-analysis from the CHARGE Consortium. Stroke 2010; 41: 210-217
106. Fornage M, Debette S, Bis JC, Schmidt H, Ikram MA, Dufouil C, et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 2011; 69: 928-939
107. Verhaaren BF, de Boer R, Vernooij MW, Rivadeneira F, Uitterlinden AG, Hofman A, et al. Replication study of chr17q25 with cerebral white matter lesion volume. Stroke 2011; 42: 3297-3299
108. Tabara Y, Igase M, Okada Y, Nagai T, Uetani E, Kido T, et al. Association of Chr17q25 with cerebral white matter hyperintensities and cognitive impairment: the J-SHIPP study. Eur J Neurol 2013; 20: 860-862
109. Adib-Samii P, Rost N, Traylor M, Devan W, Biffi A, Lanfranconi S, et al. 17q25 Locus is associated with white matter hyperintensity volume in ischemic stroke, but not with lacunar stroke status. Stroke 2013; 44: 1609-1615
110. Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng YC, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol 2012; 11: 951-962
111. Kochunov P, Glahn D, Lancaster J, Winkler A, Kent JW Jr., Olvera RL, et al. Whole brain and regional hyperintense white matter volume and blood pressure: overlap of genetic loci produced by bivariate, wholegenome linkage analyses. Stroke 2010; 41: 2137-2142
112. Turner ST, Fornage M, Jack CR Jr, Mosley TH, Knopman DS, Kardia SL, et al. Genomic susceptibility loci for brain atrophy, ventricular volume, and leukoaraiosis in hypertensive sibships. Arch Neurol 2009; 66: 847-857
113. Jickling GC, Stamova B, Ander BP, Zhan X, Tian Y, Liu D, et al. Profiles of lacunar and nonlacunar stroke. Ann Neurol 2011; 70: 477-485
114. Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, et al. Expression profile of MicroRNAs in young stroke patients. PLoS One 2009; 4: e7689
115. Jeon YJ, Kim OJ, Kim SY, Oh SH, Oh D, Shin BS, et al. Association of the miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with ischemic stroke and silent brain infarction risk. Arterioscler Thromb Vasc Biol 2013; 33: 420-430
116. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822-838
117. Oncel C, Demir S, Guler S, Cenikli U, Tabak E and Kiroglu Y. Association between cholesterols, homocysteine and silent brain infarcts. Intern Med J 2009; 39: 150-155
118. Park SY, An SA, Lee HB, Kim Y, Kim NK, Kim SH, et al. Different impact of hyperhomocysteinemia on cerebral small vessel ischemia and cervico-cerebral atherosclerosis in non-stroke individuals. Thromb Res 2013; 131: e12-e16
119. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 2002; 51: 285-289
120. Matsui T, Arai H, Yuzuriha T, Yao H, Miura M, Hashimoto S, et al. Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke 2001; 32: 1116-1119
121. Ravera M, Ratto E, Vettoretti S, Viazzi F, Leoncini G, Parodi D, et al. Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. J Nephrol 2002; 15: 519-524
122. Kawamura T, Umemura T, Kanai A, Uno T, Matsumae H, Sano T, et al. The incidence and characteristics of silent cerebral infarction in elderly diabetic patients: association with serum-soluble adhesion molecules. Diabetologia 1998; 41: 911-917
123. Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Oda N, Tanaka A, et al. Silent brain infarction and platelet activation in obstructive sleep apnea. Am J Respir Crit Care Med 2007; 175: 612-617
124. Henskens LH, Kroon AA, van Boxtel MP, Hofman PA and de Leeuw PW. Associations of the angiotensin II type 1 receptor A1166C and the endothelial NO synthase G894T gene polymorphisms with silent subcortical white matter lesions in essential hypertension. Stroke 2005; 36: 1869-1873
125. Gormley K, Bevan S and Markus HS. Polymorphisms in genes of the renin-angiotensin system and cerebral small vessel disease. Cerebrovasc Dis 2007; 23: 148-155
126. Takami S, Imai Y, Katsuya T, Ohkubo T, Tsuji I, Nagai K, et al. Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study. Am J Hypertens 2000; 13: 121-127
127. van Rijn MJ, Bos MJ, Isaacs A, Yazdanpanah M, Arias-Vasquez A, Stricker BH, et al. Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology. J Neurol Neurosurg Psychiatry 2007; 78: 1083-1087
128. Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Fodor L, Bene J, et al. Specific APO E genotypes in combination with the ACE D/D or MTHFR 677TT mutation yield an independent genetic risk of leukoaraiosis. Acta Neurol Scand 2004; 109: 222-227
129. Lemmens R, Gorner A, Schrooten M and Thijs V. Association of apolipoprotein E epsilon2 with white matter disease but not with microbleeds. Stroke 2007; 38: 1185-1188
130. Notsu Y, Nabika T, Park HY, Masuda J and Kobayashi S. Evaluation of genetic risk factors for silent brain infarction. Stroke 1999; 30: 1881-1886
131. Hong SH, Park HM, Ahn JY, Kim OJ, Hwang TS, Oh D, et al. ACE I/D polymorphism in Korean patients with ischemic stroke and silent brain infarction. Acta Neurol Scand 2008; 117: 244-249
132. Purandare N, Oude Voshaar RC, Davidson Y, Gibbons L, Hardicre J, Byrne J, et al. Deletion/insertion polymorphism of the angiotensin-converting enzyme gene and white matter hyperintensities in dementia: a pilot study. J Am Geriatr Soc 2006; 54: 1395-1400
133. Tascilar N, Dursun A, Ankarali H, Mungan G, Ekem S and Baris S. Angiotensin-converting enzyme insertion/ deletion polymorphism has no effect on the risk of atherosclerotic stroke or hypertension. J Neurol Sci 2009; 285: 137-141
134. Han IB, Kim OJ, Ahn JY, Oh D, Hong SP, Huh R, et al. Association of methylenetetrahydrofolate reductase (MTHFR 677C
135. Reitz C, Berger K, de Maat MP, Stoll M, Friedrichs F, Kardys I, et al. CRP gene haplotypes, serum CRP, and cerebral small-vessel disease: the Rotterdam Scan Study and the MEMO Study. Stroke 2007; 38: 2356-2359.